The investigational oral synthetic androgen dimethandrolone undecanoate (DMAU) suppresses serum testosterone levels to near castrate levels and appears safe when taken once daily for a month, showing potential as a male contraceptive pill, according to a study.
Individuals with obesity but without diabetes experienced significant weight reduction with daily doses of the glucagon-like peptide-1 receptor agonist semaglutide, according to a recent study presented at ENDO 2018.
The use of a hybrid closed-loop insulin pump, which has shown promise in improving glycaemic outcomes in adolescents and adults with type 1 diabetes, may also be beneficial in children, according to a study presented at ENDO 2018.
Impaired endothelial-dependent microvascular reactivity appears to be predictive of albuminuria progression in Asian patients with type 2 diabetes (T2D) who have normal urine albumin levels at baseline, but not in those with microalbuminuria, a prospective longitudinal cohort study suggests.
Individuals with severe obesity who undergo Roux-en-Y gastric bypass (RYGB) may have a higher risk of nonvertebral fractures than those who undergo adjustable gastric banding (AGB), according to a study presented at the recent ENDO 2018 sessions.
Using real-time continuous glucose monitoring (rtCGM) reduces hypoglycaemia events compared with self-monitoring of blood glucose (SMBG) in people with type 1 diabetes (T1D) who are treated with multiple daily insulin (MDI) injections and are at high risk for severe hypoglycaemia, according to the HypoDE* study.
Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.